Sickle Cell Disease News Home | Sickle Cell Disease News
WEB1 day ago · Low-intensity stem cell transplants, which use milder conditioning regimens, appear not to damage the lungs and may even improve lung function in adults with sickle cell disease (SCD), according to a new study led by scientists from the National Institutes of Health (NIH). “By using a low-intensity blood…. August 30, 2024 Columns by Mary ...
This Sickle Cell Awareness Month, I’m reflecting on why I advocate
WEB1 day ago · As we observe Sickle Cell Awareness Month, I urge everyone to join me in amplifying awareness and advocacy efforts. Together, we can bridge the knowledge gap surrounding sickle cell disease, eliminate stigma and discrimination, boost research and support, and ultimately enhance patients’ quality of life. Let’s work together to make every ...
Vaso-Occlusive Crisis - Sickle Cell Disease News
WEBJan 4, 2022 · A vaso-occlusive crisis, or VOC, occurs when sickled red blood cells block blood flow to the point that tissues become deprived of oxygen. This in turn sets in motion an inflammatory response as the body tries to rectify the problem. The result is substantial pain, which can affect any part of the body, but most commonly occurs in the back ...
Here's what we can do for National Sickle Cell Awareness Month
WEB3 days ago · For the sickle cell disease community, September is an important time for advocacy and raising awareness, because it’s National Sickle Cell Awareness Month. This year’s theme is “Sickle Cell Matters.”. For me, the month isn’t only about raising awareness; it’s also about educating the public, advocating for better healthcare, and ...
Testing of SCD Gene Therapy Lovo-cel Resumes After Holdup
WEBDec 22, 2022 · HGB-206 (NCT02140554) is an ongoing Phase 1/2 study that’s evaluating the safety and effectiveness of lovo-cel in up to 50 people, ages 12 to 50, with a diagnosis of SCD. The study includes three treatment groups — A, B, and C. All 35 patients in Group C received lovo-cel, after which they were followed for a median of 20.9 months.
FDA clears study of potentially less toxic SCD conditioning regimen
WEBJul 30, 2024 · The U.S. Food and Drug Administration (FDA) gave the greenlight for Iomab-ACT, a potentially less toxic conditioning regimen, to be tested in people with sickle cell disease (SCD) undergoing a stem cell transplant. The study will be conducted in collaboration between Actinium Pharmaceuticals, which is …
Top 10 Sickle Cell Disease Stories of 2022
WEBDec 29, 2022 · Here we’ve compiled a list of the 10 most-read articles published on our site in 2022, with a brief description of each. No. 10 — “ Trial of Cell Therapy to Raise HbF Levels Showing Potential, But Sanofi Leaving ”. SAR445136 is a gene-edited cell therapy designed to boost the production of fetal hemoglobin (HbF) in a patient’s blood ...
Approved treatments for sickle cell disease
WEBCasgevy (exagamglogene autotemcel), formerly known as CTX001 or exa-cel, is an approved gene-editing therapy used for people with SCD who experience recurrent vaso-occlusive crises. It is designed to reduce the frequency and severity of these painful crises. The one-time therapy is designed to be administered via an intravenous or into-the-vein ...
Infections are a silent menace for many with sickle cell disease
WEBMar 27, 2024 · Sickle cell disease predisposes people to infections and can aggravate the severity of an infection by compromising the immune system. The spleen is a vital organ in the immune system, responsible for filtering blood, removing old or damaged cells, and producing antibodies. In sickle cell disease, the sickling of red blood cells can impair ...
Blood transfusion for sickle cell disease
WEBAug 16, 2024 · A blood transfusion is a medical procedure through which healthy blood cells or blood components are transferred from a healthy donor to someone in need. It may be used to help treat, mitigate, or prevent the symptoms and chronic complications of sickle cell disease (SCD) in both children and adults. SCD is a disorder that impacts red blood ...
Skip to content